| 田一童,刘成成,陈晓锋.多西他赛联合奥沙利铂及S-1新辅助化疗后手术加辅助S-1与直接手术加辅助S-1治疗可切除晚期胃癌的Ⅲ期对比研究——PRODIGY研究解读[J].肿瘤学杂志,2022,28(4):336-344. |
| 多西他赛联合奥沙利铂及S-1新辅助化疗后手术加辅助S-1与直接手术加辅助S-1治疗可切除晚期胃癌的Ⅲ期对比研究——PRODIGY研究解读 |
| Summary of A Phase Ⅲ Study（PRODIGY） of Neoadjuvant Docetaxel，Oxaliplatin，and S-１ Plus Surgery and Adjuvant S-１ Versus Surgery and Adjuvant S-１ for Resectable Advanced Gastric Cancer |
| 投稿时间：2022-04-12 |
| DOI：10.11735/j.issn.1671-170X.2022.04.B015 |
|
 |
| 中文关键词: 胃癌 新辅助治疗 辅助治疗 临床研究 |
| 英文关键词:gastric cancer neoadjuvant therapy adjuvant therapy clinical research |
| 基金项目: |
|
| 摘要点击次数: 805 |
| 全文下载次数: 246 |
| 中文摘要: |
| 摘 要：PRODIGY研究是一项对可切除晚期胃癌患者进行新辅助多西他赛联合奥沙利铂及S-1（DOS）治疗后手术加辅助S-1（CSC组）与直接手术加辅助S-1（SC组）的疗效差异比较的研究。研究对象按部位和cTNM分期进行分层，通过交互式网络响应系统将患者（1∶1）随机分配到CSC组或SC组。主要研究终点为无进展生存时间（PFS）。该研究有1次中期分析，组间差异未达到预先设定的显著性阈值（0.0 031），故未中途终止研究。最终分析提示，两组共发生183例PFS事件，CSC组的PFS较SC组明显延长；亚组分析提示分期较晚的胃癌患者获益更显著，且安全性可接受。新辅助DOS后D2胃切除术联合术后S-１辅助化疗可作为亚洲人群可切除性进展期胃癌的一种治疗选择。 |
| 英文摘要: |
| Abstract： The PRODIGY study is a study comparing the efficacy of neoadjuvant DOS (docetaxel plus oxaliplatin， S-１) followed by surgery plus adjuvant S-１(CSC group) and post-operative adjuvant S-１(SC group) in patients with resectable advanced gastric cancer. Subjects were stratified by site and cTNM staging， and patients were randomly assigned(1∶1) to CSC or SC group by interactive web-response system. The primary endpoint was progression free survival. The study had 1 interim analysis while the difference did not reach the prespecified significance threshold(0.0 031)， and the study continued. In the final analysis， a total of 183 PFS events were identified. The results showed that PFS was significantly prolonged in the CSC group compared with the SC group with acceptable safety， and the benefit was more pronounced for patients with advanced gastric cancer. Neoadjuvant DOS followed by surgery plus adjuvant S-１ may be a treatment option for resectable advanced gastric cancer in Asia. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |